Inflammatory bowel disease is characterized by significant interindividual heterogeneity. With a wider selection of pharmacologic and nonpharmacologic interventions available and in advanced developmental stages, a priority for the coming decade is to determine accurate methods of predicting treatment response and disease course. Precision medicine strategies will allow tailoring of preventative and therapeutic decisions to individual patient needs. In this review, we consider the future of precision medicine in inflammatory bowel disease. We discuss the critical need to extend from research focused on short-term symptomatic response to integrative multi-omic systems biology strategies to identify and validate biomarkers that underpin precision approaches. Crucially, the international community has collective responsibility to provide well-phenotyped and -curated longitudinal datasets for scientific discovery and validation. Research must also study broader aspects of the immune response, including components of the extracellular matrix, to better understand biological pathways initiating and perpetuating tissue fibrosis and longer-term disease complications.

中文翻译：

---

精准医学预测炎症性肠病结果和控制组织重塑的未来


炎症性肠病的特点是显着的个体间异质性。随着药物和非药物干预措施的选择范围越来越广，并且处于后期发展阶段，未来十年的首要任务是确定预测治疗反应和病程的准确方法。精准医学策略将允许根据个体患者的需求制定预防和治疗决策。在这篇综述中，我们考虑了炎症性肠病精准医学的未来。我们讨论了从关注短期症状反应的研究扩展到综合多组学系统生物学策略的迫切需要，以识别和验证支持精确方法的生物标志物。至关重要的是，国际社会有集体责任为科学发现和验证提供表型良好且精心策划的纵向数据集。研究还必须研究免疫反应的更广泛方面，包括细胞外基质的成分，以更好地了解引发和维持组织纤维化以及长期疾病并发症的生物途径。